Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.
University of Michigan Rogel Cancer Center
Summary
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.
Eligibility
- Age range
- 3+ years
- Sex
- All
- Healthy volunteers
- Not specified
Inclusion Criteria: * For both Cohorts 1 and 2: * Age ≥ 36 months. There is no upper age limit. * Receipt of an allogeneic HCT. There are no exclusions to study entry based upon primary diagnosis, hematopoietic cell source, conditioning regimen, donor type, degree of donor-recipient HLA match, or current organ function. * All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines. * Cohort 1 (Chronic Graft Versus Host Disease): Diagnosis of chronic GVHD in at least 1 organ system w…
Locations (6)
- Stanford HospitalStanford, California
- Emory UniversityAtlanta, Georgia
- Dana FarberBoston, Massachusetts
- The University of Michigan Cancer CenterAnn Arbor, Michigan
- MD AndersonHouston, Texas
- Fred Hutchinson Cancer Research CenterSeattle, Washington